Table 3 Correlation between VEGF and SEMA4D expression and clinicopathologic characteristics of EOC patients
Variable | Cases (N) | SEMA4D positive expression | VEGF positive expression | ||
|---|---|---|---|---|---|
n (%) | p | n (%) | p | ||
Age | 0.078 | 0.431 | |||
≤ 50 years | 60 | 32 (53.3) | 23 (38.3) | ||
> 50 years | 64 | 44 (68.8) | 29 (45.3) | ||
Menopausal status | 0.223 | 0.913 | |||
Yes | 78 | 51 (65.4) | 33 (42.3) | ||
No | 46 | 25 (54.3) | 19 (41.3) | ||
Pathologic type | 0.709 | 0.581 | |||
Serous carcinoma | 80 | 50 (62.5) | 35 (43.8) | ||
Mucous and others | 44 | 26 (59.1) | 17 (38.6) | ||
Histologic grade | 0.000 | 0.039 | |||
G1-2 | 49 | 20 (40.8) | 15 (30.6) | ||
G3 or undifferentiated | 75 | 56 (74.7) | 37 (49.3) | ||
FIGO Stage | 0.016 | 0.000 | |||
I–II | 53 | 26 (49.1) | 8 (15.1) | ||
III–IV | 71 | 50 (70.4) | 44 (62.0) | ||
LN metastasis | 0.017 | 0.062 | |||
No | 74 | 39 (52.7) | 26 (35.1) | ||
Yes | 50 | 37 (74.0) | 26 (52.0) | ||
Residual disease | 0.004 | 0.304 | |||
< 1 cm | 94 | 51 (54.3) | 37 (39.4) | ||
≥ 1 cm | 30 | 25 (83.3) | 15 (50.0) | ||
Patients’ response to chemotherapy | 0.349 | 0.010 | |||
CR | 87 | 51 (58.6) | 30 (34.5) | ||
PR, SD and PD | 37 | 25 (67.6) | 22 (59.5) | ||
Tumor sensitivity to chemotherapy | 0.315 | 0.006 | |||
Platinum sensitive | 92 | 54 (58.7) | 32 (34.8) | ||
Platinum resistant and refractory | 32 | 22 (68.8) | 20 (62.5) | ||